Literature DB >> 27411321

Models of In-Vivo Bacterial Infections for the Development of Antimicrobial Peptide-based Drugs.

Jlenia Brunetti, Chiara Falciani1, Luisa Bracci, Alessandro Pini.   

Abstract

The increasing frequency of multi-resistant Gram-positive and Gram-negative bacteria and a long-term decreasing trend in the development of new antimicrobial molecules prompts research for new anti-infective agents with new modes of action. Antimicrobial peptides (AMPs) are considered an interesting class of antibacterial molecules. Many new AMPs have been discovered and some are being evaluated for the development of new antibacterial therapeutics. Since the development of new antibacterial drugs has been neglected for decades, we are now faced with extreme medical need combined with a lack of technical experimental progress in setting up efficient models of antibacterial activity in animals. Here we review experiments with AMPs in animal models of sepsis, pneumonia and skin infection caused by bacteria. Animal models of infection have been of enormous predictive value in antibacterial drug discovery, both for elucidating AMP efficacy in the treatment of experimentally induced infection and for comparing the effectiveness of two or more antibiotics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27411321     DOI: 10.2174/1568026616666160713143017

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

1.  Discovery of Next-Generation Antimicrobials through Bacterial Self-Screening of Surface-Displayed Peptide Libraries.

Authors:  Ashley T Tucker; Sean P Leonard; Cory D DuBois; Gregory A Knauf; Ashley L Cunningham; Claus O Wilke; M Stephen Trent; Bryan W Davies
Journal:  Cell       Date:  2018-01-04       Impact factor: 41.582

2.  In Vitro and In Vivo Antibiotic Capacity of Two Host Defense Peptides.

Authors:  Iván Arenas; Marco Antonio Ibarra; Felix L Santana; Elba Villegas; Robert E W Hancock; Gerardo Corzo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-06-07       Impact factor: 2.649

4.  Azithromycin-loaded linolenic acid-modified methoxy poly(ethylene glycol) micelles for bacterial infection treatment.

Authors:  Yi Wen; Zhimei Song; Hongmei Xu; Sijia Feng; Li Zhu; Fangfang Teng; Runliang Feng
Journal:  Drug Deliv Transl Res       Date:  2021-03-14       Impact factor: 4.617

5.  Predatory Bacteria Attenuate Klebsiella pneumoniae Burden in Rat Lungs.

Authors:  Kenneth Shatzkes; Eric Singleton; Chi Tang; Michael Zuena; Sean Shukla; Shilpi Gupta; Sonal Dharani; Onoyom Onyile; Joseph Rinaggio; Nancy D Connell; Daniel E Kadouri
Journal:  MBio       Date:  2016-11-08       Impact factor: 7.867

6.  Antimicrobial efficacy and toxicity of novel CAMPs against P. aeruginosa infection in a murine skin wound infection model.

Authors:  Ming Yang; Chunye Zhang; Sarah A Hansen; William J Mitchell; Michael Z Zhang; Shuping Zhang
Journal:  BMC Microbiol       Date:  2019-12-16       Impact factor: 3.605

Review 7.  Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.

Authors:  Derry K Mercer; Deborah A O'Neil
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

8.  Immunomodulatory and Anti-inflammatory Activity in Vitro and in Vivo of a Novel Antimicrobial Candidate.

Authors:  Jlenia Brunetti; Giulia Roscia; Ilaria Lampronti; Roberto Gambari; Leila Quercini; Chiara Falciani; Luisa Bracci; Alessandro Pini
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.